dc.contributor.author | Yenidunya, G. | |
dc.contributor.author | Bekpinar, S. | |
dc.contributor.author | Dinccag, N. | |
dc.contributor.author | Aycan-Ustyol, E. | |
dc.contributor.author | Gurdol, F. | |
dc.contributor.author | Unlucerci, Y. | |
dc.date.accessioned | 2021-03-06T21:09:15Z | |
dc.date.available | 2021-03-06T21:09:15Z | |
dc.date.issued | 2015 | |
dc.identifier.citation | Bekpinar S., Yenidunya G., Gurdol F., Unlucerci Y., Aycan-Ustyol E., Dinccag N., "The effect of nephropathy on plasma sphingosine 1-phosphate concentrations in patients with type 2 diabetes", CLINICAL BIOCHEMISTRY, cilt.48, ss.1264-1267, 2015 | |
dc.identifier.issn | 0009-9120 | |
dc.identifier.other | av_fd6da283-90dd-459c-8e2e-184950a7dde7 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/165790 | |
dc.identifier.uri | https://doi.org/10.1016/j.clinbiochem.2015.08.001 | |
dc.description.abstract | Objectives: Sphingosine 1-phosphate (S1P) is carried in plasma by the HDL particles and albumin. It mediates several protective functions of HDL. Because of its barrier-enhancing effect, it has attracted attention in diseases associated with endothelial dysfunction. We examined the impact of circulating levels of S1P in diabetic nephropathy together with apoprotein M, a S1P-binding protein in HDL. Plasma levels of dimethylarginines were evaluated in this context. | |
dc.language.iso | eng | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Sağlık Bilimleri | |
dc.subject | TIBBİ LABORATUVAR TEKNOLOJİSİ | |
dc.subject | Klinik Tıp | |
dc.subject | Tıp | |
dc.title | The effect of nephropathy on plasma sphingosine 1-phosphate concentrations in patients with type 2 diabetes | |
dc.type | Makale | |
dc.relation.journal | CLINICAL BIOCHEMISTRY | |
dc.contributor.department | İstanbul Üniversitesi , , | |
dc.identifier.volume | 48 | |
dc.identifier.issue | 18 | |
dc.identifier.startpage | 1264 | |
dc.identifier.endpage | 1267 | |
dc.contributor.firstauthorID | 226484 | |